We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
SER | Strategic Energy Resources Limited | 0.033 | 0.017 | 106.25% | 103,636,351 | 1,072 |
RR1OA | Reach Resources Ltd | 0.007 | 0.003 | 75.00% | 84,054 | 3 |
KED | Keypath Education International Inc | 0.83 | 0.295 | 55.14% | 499,536 | 92 |
REEO | RareX Limited | 0.003 | 0.001 | 50.00% | 1,158,605 | 3 |
CPOO | Culpeo Minerals Ltd | 0.006 | 0.002 | 50.00% | 526,390 | 1 |
AN1 | Anagenics Ltd | 0.01 | 0.003 | 42.86% | 5,481,308 | 57 |
T3D | 333D Limited | 0.008 | 0.002 | 33.33% | 487,613 | 3 |
GMN | Gold Mountain Limited | 0.004 | 0.001 | 33.33% | 7,853,019 | 16 |
EDE | Eden Innovations Ltd | 0.002 | 0.0005 | 33.33% | 1,914,026 | 4 |
NAE | New Age Exploration Limited | 0.004 | 0.001 | 33.33% | 885,170 | 6 |
FTZ | Fertoz Limited | 0.04 | 0.01 | 33.33% | 33,338 | 3 |
NEW YORK, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- On May 17, 2024, SCWorx Corp. (the “Company”) received a further notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q for the period ended March 31, 2024, and because it remains delinquent in filing its Form 10-K for the year ended December 31, 2023, the Company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC. ...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff Delisting Determination notified the Company that since it has not yet filed its Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) per Nasdaq Listing Rule 5250(c)(1) (the “Rule”) by Nasdaq’s extended deadline of May 20, 2024 pursuant to the previously granted exception, trading of the Company’s common stock would be suspended from The Nasdaq Capital Market at the opening of business ...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange (as defined below). The purpose of the Offer and Consent Solicitation is to simplify the Company’s capital structure and reduce the potential dilutive impact of the Warrants, thereby providing the Company with more flexibility for financing its operations in the future.
TULSA, Okla., May 23, 2024 /PRNewswire/ -- ClearSign Technologies Corporation (Nasdaq: CLIR) ("ClearSign" or the "Company"), an emerging leader in industrial combustion and sensing technologies that improve energy, operational efficiency and safety while dramatically reducing emissions, today provides an update on operations for the quarter ended March 31, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,881.90 | -38.84 | -0.06% | 1.33T | 5,704,663,302 |
ETH | Ethereum | 3,721.41 | -54.11 | -1.43% | 445.01B | 9,184,313,401 |
USDT | Tether USD | 0.9993 | -0.00016 | -0.02% | 97.76B | 318,670,093 |
BNB | Binance Coin | 597.94 | -0.819416 | -0.14% | 94.56B | 420,150,562 |
SOL | Solana | 168.31 | -7.70 | -4.38% | 73.62B | 1,922,698,915 |
STETH | stETH | 3,715.01 | -59.38 | -1.57% | 36.41B | 54,429,808 |
XRP | Ripple | 0.5358 | 0.0073 | 1.38% | 29.11B | 567,659,188 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 1,604,034,710 |
DOGE | Dogecoin | 0.16516 | 0.00553 | 3.46% | 23.49B | 1,008,715,881 |
TONCOIN | Wrapped TON Coin | 6.22 | -0.003321 | -0.05% | 21.54B | 120,508,027 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions